By using our website, you are agreeing to cookies being stored and Google Analytics being used on your device in order to offer the best possible service. You can find more information on thishere.
Austria.
Where Your Profits Grow Sky High.

Austrians as finalists in the biggest programme searching for drugs against COVID-19

Innophore team © Innophore

Drugs are the focus of a stable path out of a global crisis. In particular, the search in the GrandChallenge is particularly on new drugs with a strong impact on the essential target proteins of the SARS-CoV-2 virus. Participants were asked to validate at least one billion molecules on the basis of three different calculation methods. Artificial intelligence and digital medicine are playing an important role in the process.

"130 teams consisting of more than 500 scientists at the best institutions across the globe screened more than 54 billion molecules. The VirtualFlow Team with scientists from Austria (Innophore, University of Graz and acib), the USA (Harvard, DFCI, Google and University of California, Berkeley), Germany (Max-Planck-Institute and the Berlin University of Technology) and the Ukraine (Enamine and Chemspace) are now among the finalists and are competing with the few other remaining drug discovery teams to win the prestigious COVID-19 GrandChallenge organised by the Joint European Disruptive Initiative (JEDI), the European equivalent of DARPA (Defense Advanced Research Projects Agency). It is interesting to observe the fact that only team submitting drug proposal with real potential to treat COVID9 were chosen to take part in the round of finalists", emphasizes Prof. Thomas Hermans, Programme Manager of the JEDI Covid19 GrandChallenge.

"878 of the new substances proving to be promising in the computer experiments and which have not been used up until now against COVID-19 were synthesized and are now being experimentally investigated in test tubes and directly on living cells infected with SARS-CoV-2. These analyses are being carried out in independent, high-security laboratories in Germany, France and the USA. Several of them have come from our JEDI team and are now being published as open science in the specialised media", explains Georg Steinkellner, CTO of Innophore. "Being accepted in the finals is an important milestone for Innophore, a further proof-of-principle for our patented CatalophoreTM AI technology and last but not least, a great honour, says Christian Gruber, CEO of the Graz-based, high-tech firm.

Go on reading and find out more about life sciences research in Austria!

Read more:

Share on Facebook Share on Facebook Share on Twitter Share on Twitter Share on Linkedin Share on Linkedin

Testimonials

Events

Meet us at events, seminars and trade shows - worldwide.

  • Meet us @ BIO-Europe

    25.10.2021 - 28.10.2021/ 07.30am - 06.00pm, Virtual Event

Austria Map

Find the perfect location for your company

Austria stands out due to its long-term reliable and stable conditions. These features are particularly important for a research-based company such as Boehringer Ingelheim. Furthermore, Vienna is a city with a good research infrastructure and a high quality of life, and is thus also an interesting place for highly qualified employees from Austria and abroad.

Boehringer Ingelheim

Logo
More testimonials

news from the business location Austria

Austria stands out due to its tax incentives for research

You want to know why companies such as Infineon, Siemens and Bosch have been carrying out research in Austria for decades? Contact us.

Lynus – the software for the enegery-optimized building of the future.

The business location Austria offers innovative businesses such as Lynus the right platform, a modern environment, and highly skilled workforce in order to use complex IOT solutions with ease. Additionally the desire of a lot of Austrian companies to minimize their CO2 footprint in a sustainable way, appeals very much to our business model.

More news All blog posts